Rotateq Related Published Studies
Well-designed clinical trials related to Rotateq (Rotavirus Vaccine)
Methodology and lessons-learned from the efficacy clinical trial of the
pentavalent rotavirus vaccine in Bangladesh. [2012]
Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya,
including among HIV-infected and HIV-exposed infants. [2012]
Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian
children in the first two years of life: a randomized, double-blind, placebo
controlled trial. [2012]
Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine. [2011.05]
[Rotavirus vaccine]. [Article in Japanese] [2011]
Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe. [2010.12.01]
Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. [2010.12]
Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. [2010.11]
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. [2010.08.21]
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. [2010.08.21]
Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe. [2010.06.18]
Vaccines for preventing rotavirus diarrhoea: vaccines in use. [2010.05.12]
Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. [2010.03]
Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of
rotavirus gastroenteritis in Europe. [2010]
Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity
of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral
polio vaccine in South African infants. [2010]
Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered
with routine infant vaccines following the vaccination schedules in Europe. [2010]
Co-administration study in South African infants of a live-attenuated oral human
rotavirus vaccine (RIX4414) and poliovirus vaccines. [2010]
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. [2009.12.11]
Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. [2009.04]
Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. [2009.03]
Rotavirus live, oral, pentavalent vaccine. [2007.12]
Well-designed clinical trials possibly related to Rotateq (Rotavirus Vaccine)
Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the
first two years of life. [2011]
Other research related to Rotateq (Rotavirus Vaccine)
Vaccines for preventing rotavirus diarrhoea: vaccines in use. [2012]
Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against
rotavirus gastroenteritis among American Indian children. [2012]
Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to
standard supportive therapy for rotavirus-associated diarrhea among pediatric
patients. [2012]
Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in
South African children over two consecutive rotavirus-seasons: a randomized,
double-blind, placebo-controlled trial. [2012]
Rotavirus vaccines: safety, efficacy and public health impact. [2011.09]
Projecting the effectiveness of RotaTeq(R) against rotavirus-related hospitalisations in Brazil. [2011.08]
Effectiveness of pentavalent rotavirus vaccine against severe disease. [2011.08]
Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. [2011.05.31]
Projecting the effectiveness of RotaTeq(R) against rotavirus-related hospitalizations and deaths in six Asian countries. [2011.05]
Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. [2011.04.05]
Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine. [2011.03]
Changes in childhood diarrhea incidence in nicaragua following 3 years of universal infant rotavirus immunization. [2011.03]
United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. [2011.01]
Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. [2011.01]
Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. [2011.01]
Rotavirus vaccines: safety, efficacy and public health impact. [2011]
Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a
3-dose series and with less than 3 doses (incomplete regimen). [2011]
Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. [2010.11.03]
Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). [2010.09.14]
RotaTeq: Progress toward developing world access. [2010.09.01]
Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. [2010.09]
Use of an immunization information system to assess the effectiveness of pentavalent rotavirus vaccine in US children. [2010.08.31]
Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain. [2010.08.10]
Performance of rotavirus vaccines in developed and developing countries. [2010.07]
Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). [2010.06.11]
Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. [2010.05.14]
Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. [2010.02]
Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. [2010.02]
Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. [2010.02]
Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. [2010.01]
Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to
3 years of age: the Finnish Extension Study. [2010]
Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine
when administered with greater than 10 weeks between doses. [2010]
Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. [2009.12.30]
Estimated research and development costs of rotavirus vaccines. [2009.11.05]
Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception. [2009.11.01]
Intussusception and rotavirus vaccination: a review of the available evidence. [2009.11]
Discovery of rotavirus: Implications for child health. [2009.10]
Prevention of the murine model of biliary atresia after live rotavirus vaccination of dams. [2009.08]
A critical review on a globally-licensed, live, orally-administrable, monovalent human rotavirus vaccine: Rotarix. [2009.08]
Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. [2009.08]
Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. [2009.07.17]
Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. [2009.06.19]
Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. [2009.06.03]
Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. [2009.06]
Rotaviruses: from pathogenesis to vaccination. [2009.05]
Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). [2009.02.06]
Rotavirus vaccines and pathogenesis: 2008. [2009.01]
RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. [2008.12]
[Rotavirus vaccine] [2008.10]
Assessing the introduction of universal rotavirus vaccination in the Netherlands. [2008.07.04]
Characteristics of an ideal rotavirus vaccine. [2008.07]
Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. [2008.07]
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. [2008.06]
RotaTeq vaccine adverse events and policy considerations. [2008.03]
Rotavirus vaccines: an overview. [2008.01]
Rotavirus vaccines. [2008]
Evaluating the safety of a rotavirus vaccine: the REST of the story. [2008]
Prevention of childhood rotavirus disease through the use of Rotarix and RotaTeq vaccines. [2007.12]
A qualitative assessment of factors influencing acceptance of a new rotavirus vaccine among health care providers and consumers. [2007.10.18]
Rotavirus vaccines: entering a new stage of deployment. [2007.10]
Preventing rotavirus gastroenteritis: do you have the facts? [2007.07]
Rotavirus vaccines: recent developments and future considerations. [2007.07]
[Active immunization against acute gastro-enteritis among young children, caused by rotaviruses] [2007]
Other possibly related research studies
Preconceptional oral vaccination prevents experimental biliary atresia in newborn mice. [2010.05]
Prevention and treatment of viral diarrhea in pediatrics. [2010.02]
Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. [2009.11]
|
